Take a look back at every Kia Rookie of the Year award winner in NBA history. Look back at the winners of every NBA award, All-NBA team and more in NBA history. Take a look back at every Kia ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang ...

Editor's note: This column originally ran in the Detroit Free Press on April 11, 1986. Chet Lemon died on May 8, 2025. A note from Mitch: I was deeply saddened to learn of the passing of Chet Lemon.

EXEL boasts a Value Style Score of B and VGM Score of A, and holds a Zacks Rank #2 (Buy) rating. Shares of Exelixis are trading at a forward earnings multiple of 16.8X, as well as a PEG Ratio of 0 ...

Former Detroit Tigers center fielder Chet Lemon, a key member of the 1984 World Series championship team, has died at age 70. Lemon's impact extended beyond his MLB career through his youth ...

Chet Lemon, a 16-year MLB veteran and 1984 World Series champion, died on Thursday. He was 70. “He was sleeping on his reclining sofa,” his wife, Gigi Lemon, told the Detroit Free Press. “He ...

Chet Holmgren, fully recovered from a pelvic fracture, is set to play a crucial role in Game 4 against the Timberwolves. After a devastating Game 3 loss, the Thunder need Holmgren's defensive ...

The baseball world mourns the loss of Chet Lemon, who passed away at 70. A three-time All-Star and 1984 World Series champion with the Detroit Tigers, Lemon battled health issues, including a rare ...

On Wednesday night, Chet Holmgren and the OKC Thunder punched their ticket to the NBA Finals by eliminating the Minnesota Timberwolves. Following their Game 5 victory, the former No. 2 pick sent ...

Thunder's Chet Holmgren Opens Up on Early Season Injury Struggles Before NBA Finals originally appeared on Athlon Sports. It's been a dominant season for Chet Holmgren and the Oklahoma City ...

Exelixis EXEL announced encouraging results from an expansion cohort of the early to mid-stage study of its next-generation oral TKI, zanzalintinib, in combination with either Bristol Myers' BMY ...